1. Home
  2. PLRX vs PCRX Comparison

PLRX vs PCRX Comparison

Compare PLRX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pliant Therapeutics Inc.

PLRX

Pliant Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

93.3M

Sector

Health Care

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$26.30

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLRX
PCRX
Founded
2015
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.3M
1.0B
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
PLRX
PCRX
Price
$1.23
$26.30
Analyst Decision
Hold
Strong Buy
Analyst Count
11
7
Target Price
$3.79
$32.86
AVG Volume (30 Days)
1.9M
916.7K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.47
Revenue
N/A
$716,791,000.00
Revenue This Year
N/A
$6.24
Revenue Next Year
N/A
$9.53
P/E Ratio
N/A
$55.91
Revenue Growth
N/A
3.14
52 Week Low
$1.10
$18.17
52 Week High
$14.30
$27.64

Technical Indicators

Market Signals
Indicator
PLRX
PCRX
Relative Strength Index (RSI) 34.56 64.48
Support Level $1.19 $25.48
Resistance Level $1.30 $27.16
Average True Range (ATR) 0.11 1.00
MACD -0.01 0.15
Stochastic Oscillator 12.50 77.18

Price Performance

Historical Comparison
PLRX
PCRX

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: